GENINCODE PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.625 GBX | +4.05% |
|
+30.51% | +83.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 * | 2.19M 2.74M | Sales 2024 * | 4.65M 5.82M | Capitalization | 17.03M 21.33M |
|---|---|---|---|---|---|
| Net income 2023 * | -6M -7.51M | Net income 2024 * | -4M -5.01M | EV / Sales 2023 * | 7.24 x |
| Net cash position 2023 * | 1.19M 1.49M | Net cash position 2024 * | 334K 418K | EV / Sales 2024 * | 3.59 x |
| P/E ratio 2023 * |
-1.38
x | P/E ratio 2024 * |
-3.75
x | Employees | 34 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 57.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.05% | ||
| 1 week | +30.51% | ||
| Current month | +32.76% | ||
| 1 month | +6.94% | ||
| 3 months | +131.93% | ||
| 6 months | +24.19% | ||
| Current year | +83.33% |
1 week
7.00
9.76
1 month
7.009.76
Current year
3.3410.00
1 year
3.3416.00
3 years
3.3448.00
5 years
3.3448.00
10 years
3.3448.00
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Walls
FOU | Founder | 60 | 18-09-05 |
Jordi Gilberte
FOU | Founder | 49 | 18-09-05 |
Paul Foulger
DFI | Director of Finance/CFO | 55 | 20-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Foulger
DFI | Director of Finance/CFO | 55 | 20-10-31 |
Matthew Walls
FOU | Founder | 60 | 18-09-05 |
William Rhodes
CHM | Chairman | 70 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 9.625 | +4.05% | 205,017 |
| 24-05-09 | 9.25 | +2.78% | 108,769 |
| 24-05-08 | 9 | +14.29% | 182,888 |
| 24-05-07 | 7.875 | +6.78% | 365,380 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
GENinCode Plc is a United Kingdom-based predictive genetics company. The Company is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo and Thrombo Incode Reproductive Health. The Company's product portfolio draws on advanced genomic precision testing using polygenic (multiple genes) technology, molecular testing, genotyping, sequencing, and AI bioinformatics to risk assess patient DNA. Its predictive technology provides patients and physicians with global preventative care and treatment strategies. Its products combine genetic and clinical data to risk-assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. The Companyâs wholly owned subsidiaries include GENinCode S.L.U. and GENinCode U.S. INC.
Calendar
2024-05-13
- Q4 2023 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +83.33% | 21.32M | |
| -1.29% | 12.64B | |
| -0.47% | 8.46B | |
| +5.68% | 5.66B | |
| +22.61% | 5.27B | |
| -2.03% | 4.49B | |
| -53.56% | 3.11B | |
| +19.30% | 2.87B | |
| +33.07% | 2.31B | |
| -8.42% | 2.23B |
- Stock Market
- Equities
- GENI Stock